1. Refractory ascites-the contemporary view on pathogenesis and therapy
- Author
-
Halina Cichoż-Lach and Beata Kasztelan-Szczerbińska
- Subjects
medicine.medical_specialty ,Cirrhosis ,medicine.medical_treatment ,food.diet ,lcsh:Medicine ,Gastroenterology and Hepatology ,Liver transplantation ,Low sodium diet ,Gastroenterology ,Refractory ascites ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,food ,Internal medicine ,Hypovolemia ,Ascites ,medicine ,Paracentesis ,Internal Medicine ,Diuretics ,medicine.diagnostic_test ,business.industry ,General Neuroscience ,lcsh:R ,Liver crirrhosis ,Furosemide ,General Medicine ,medicine.disease ,Treatment ,chemistry ,030220 oncology & carcinogenesis ,Spironolactone ,030211 gastroenterology & hepatology ,medicine.symptom ,General Agricultural and Biological Sciences ,business ,medicine.drug - Abstract
Refractory ascites (RA) refers to ascites that cannot be mobilized or that has an early recurrence that cannot be prevented by medical therapy. Every year, 5–10% of patients with liver cirrhosis and with an accumulation of fluid in the peritoneal cavity develop RA while undergoing standard treatment (low sodium diet and diuretic dose up to 400 mg/day of spironolactone and 160 mg/day of furosemide). Liver cirrhosis accounts for marked alterations in the splanchnic and systemic hemodynamics, causing hypovolemia and arterial hypotension. The consequent activation of renin-angiotensin and sympathetic systems and increased renal sodium re-absorption occurs during the course of the disease. Cirrhotic patients with RA have poor prognoses and are at risk of developing serious complications. Different treatment options are available, but only liver transplantation may improve the survival of such patients.
- Published
- 2019